Latest Ibritumomab tiuxetan Stories
ROCKVILLE, Md., Dec. 17, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 14, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov.
DALLAS, October 29, 2014 /PRNewswire/ -- ReportsnReports.com adds Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline
- Spectrum receives a 19.99% stake (pre-transaction) in CASI, a NASDAQ-listed, oncology-focused Company with expertise and focus on markets in China and a $1.5 million promissory note HENDERSON,
In a Breaking News Exclusive, Jamie Reno writes how GSK's spokesperson informed him that Bexxar, a lifesaving cancer drug is being discontinued in February 2014.
A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.
- A trick or prank.